Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Teva CEO Steps Down While An Integration Hangs In The Balance

Executive Summary

After a damaging court ruling on Copaxone 40 mg and some management missteps, CEO Erez Vigodman will step down as CEO of the Israeli generic drug leader. Chairman Yitzhak Peterburg will fill in on an interim basis.

Advertisement

Related Content

Teva To Divest Women's Health, Some Oncology As CEO Search Proceeds
1Q Pharma Results Preview: Merck, Pfizer, Gilead, Novo Nordisk, Shire, Allergan, Teva
Teva's AirDuo Authorized Generic Priced At A 70% Discount To Advair
Copaxone 40mg Generic At-Risk Launch Anticipated As Soon As February
Teva Appoints New Global Generics Head Amid Massive Integration
Teva Hits Pause On Business Development, Even As Some Deals Stumble
Regeneron’s Fasinumab Brings Second Clinical Hold For Anti-NGF Class
Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches
Teva CEO Vigodman Reveals A First Glimpse At His Strategy
Teva Director Vigodman’s Name Floated As New CEO

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098188

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel